Review: Anti–CTLA-4 Antibody Ipilimumab: Case Studies of Clinical Response and Immune-Related Adverse Events-Reference-Cited by-同舟云学术

Review: Anti–CTLA-4 Antibody Ipilimumab: Case Studies of Clinical Response and Immune-Related Adverse Events

Published:2007-07-01 Issue:7 Volume:12 Page:864-872
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

Weber Jeffrey¹

Affiliation:

1. Comprehensive Melanoma Research Center, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA

Abstract

Learning Objectives After completing this course, the reader will be able to: Describe the completed and ongoing clinical trials of ipilimumab in patients with advanced melanoma.Discuss the nature of immune-mediated adverse events, which are often associated with ipilimumab treatment.Describe several cases illustrating the kinetics of ipilimumab-mediated antitumor responses and the relationship to immune-mediated adverse events. CME Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.TheOncologist.com

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.12-7-864

Reference18 articles.

1. CTLA-4: New insights into its biological function and use in tumor immunotherapy;Egen;Nat Immunol,2002

2. CTLA-4 and tolerance: The biochemical point of view;Chikuma;Immunol Res,2003

3. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma;Phan;Proc Natl Acad Sci U S A,2003

4. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206;Ribas;J Clin Oncol,2005

5. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4;Attia;J Clin Oncol,2005

Cited by 252 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The advancement of siRNA-based nanomedicine for tumor therapy;Nanomedicine;2024-08-15

2. Development of PET Radioisotope Copper-64-Labeled Theranostic Immunoliposomes for EGFR Overexpressing Cancer-Targeted Therapy and Imaging;International Journal of Molecular Sciences;2024-02-02

3. Immunotherapy for lung cancer;Pathology - Research and Practice;2024-02

4. Insight on the Clinical Trials of Immunotherapy for the Treatment of Lung Cancer;Immunotherapy Against Lung Cancer;2024

5. Research Progress on Colony-Stimulating Factor Combined with Radiotherapy to Fight Tumor Immunomodulation;Advances in Clinical Medicine;2024